TNFRSF17 and plasmacytoma: sBCMA was measurable in all patients, including those with solitary plasmacytoma and non‐secretory disease (2 patients) and those receiving anti‐BCMA‐targeted therapies (5 patients, treated with belantamab mafodotin and teclistamab); further details on the treatments received are provided in Table 2.